Literature DB >> 22155819

Agreement assessment of tigecycline susceptibilities determined by the disk diffusion and broth microdilution methods among commonly encountered resistant bacterial isolates: results from the Tigecycline In Vitro Surveillance in Taiwan (TIST) study, 2008 to 2010.

Jien-Wei Liu1, Wen-Chien Ko, Cheng-Hua Huang, Chun-Hsing Liao, Chin-Te Lu, Yin-Ching Chuang, Shih-Ming Tsao, Yao-Shen Chen, Yung-Ching Liu, Wei-Yu Chen, Tsrang-Neng Jang, Hsiu-Chen Lin, Chih-Ming Chen, Zhi-Yuan Shi, Sung-Ching Pan, Jia-Ling Yang, Hsiang-Chi Kung, Chun-Eng Liu, Yu-Jen Cheng, Yen-Hsu Chen, Po-Liang Lu, Wu Sun, Lih-Shinn Wang, Kwok-Woon Yu, Ping-Cherng Chiang, Ming-Hsun Lee, Chun-Ming Lee, Gwo-Jong Hsu, Po-Ren Hsueh.   

Abstract

The Tigecycline In Vitro Surveillance in Taiwan (TIST) study, initiated in 2006, is a nationwide surveillance program designed to longitudinally monitor the in vitro activity of tigecycline against commonly encountered drug-resistant bacteria. This study compared the in vitro activity of tigecycline against 3,014 isolates of clinically important drug-resistant bacteria using the standard broth microdilution and disk diffusion methods. Species studied included methicillin-resistant Staphylococcus aureus (MRSA; n = 759), vancomycin-resistant Enterococcus faecium (VRE; n = 191), extended-spectrum β-lactamase (ESBL)-producing Escherichia coli (n = 602), ESBL-producing Klebsiella pneumoniae (n = 736), and Acinetobacter baumannii (n = 726) that had been collected from patients treated between 2008 and 2010 at 20 hospitals in Taiwan. MICs and inhibition zone diameters were interpreted according to the currently recommended U.S. Food and Drug Administration (FDA) criteria and the European Committee on Antimicrobial Susceptibility Testing (EUCAST) criteria. The MIC(90) values of tigecycline against MRSA, VRE, ESBL-producing E. coli, ESBL-producing K. pneumoniae, and A. baumannii were 0.5, 0.125, 0.5, 2, and 8 μg/ml, respectively. The total error rates between the two methods using the FDA criteria were high: 38.4% for ESBL-producing K. pneumoniae and 33.8% for A. baumannii. Using the EUCAST criteria, the total error rate was also high (54.6%) for A. baumannii isolates. The total error rates between these two methods were <5% for MRSA, VRE, and ESBL-producing E. coli. For routine susceptibility testing of ESBL-producing K. pneumoniae and A. baumannii against tigecycline, the broth microdilution method should be used because of the poor correlation of results between these two methods.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22155819      PMCID: PMC3294924          DOI: 10.1128/AAC.05879-11

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  14 in total

1.  Treatment of ESBL-producing Klebsiella pneumoniae bacteraemia with carbapenems or flomoxef: a retrospective study and laboratory analysis of the isolates.

Authors:  Chen-Hsiang Lee; Lin-Hui Su; Ya-Fen Tang; Jien-Wei Liu
Journal:  J Antimicrob Chemother       Date:  2006-09-13       Impact factor: 5.790

2.  Lack of development of new antimicrobial drugs: a potential serious threat to public health.

Authors:  S Ragnar Norrby; Carl Erik Nord; Roger Finch
Journal:  Lancet Infect Dis       Date:  2005-02       Impact factor: 25.071

3.  The epidemic of antibiotic-resistant infections: a call to action for the medical community from the Infectious Diseases Society of America.

Authors:  Brad Spellberg; Robert Guidos; David Gilbert; John Bradley; Helen W Boucher; W Michael Scheld; John G Bartlett; John Edwards
Journal:  Clin Infect Dis       Date:  2008-01-15       Impact factor: 9.079

4.  Tigecycline In-vitro Surveillance in Taiwan (TIST).

Authors:  Po-Ren Hsueh
Journal:  Int J Antimicrob Agents       Date:  2008-11       Impact factor: 5.283

5.  EUCAST technical note on anidulafungin.

Authors:  M C Arendrup; J-L Rodriguez-Tudela; C Lass-Flörl; M Cuenca-Estrella; J P Donnelly; W Hope
Journal:  Clin Microbiol Infect       Date:  2011-09-16       Impact factor: 8.067

6.  Effect of medium type, age and aeration on the MICs of tigecycline and classical tetracyclines.

Authors:  R Hope; M Warner; S Mushtaq; M E Ward; T Parsons; D M Livermore
Journal:  J Antimicrob Chemother       Date:  2005-11-12       Impact factor: 5.790

7.  In-vitro activity of tigecycline against clinical isolates of Acinetobacter baumannii in Taiwan.

Authors:  Jien-Wei Liu; Lih-Shinn Wang; Yu-Jen Cheng; Gwo-Jong Hsu; Po-Liang Lu; Yung-Ching Liu; Chih-Ming Chen; Chun-Ming Lee; Wu Sun; Tsrang-Neng Jang; Ping-Cherng Chiang; Yin-Ching Chuang; Hsiu-Chen Lin; Zhi-Yuan Shi; Hsiang-Chi Kung; Cheng-Hua Huang; Shih-Ming Tsao; Chin-Te Lu; Chun-Hsing Liao; Po-Ren Hsueh
Journal:  Int J Antimicrob Agents       Date:  2008-11       Impact factor: 5.283

8.  In-vitro activity of tigecycline against clinical isolates of Acinetobacter baumannii in Taiwan determined by the broth microdilution and disk diffusion methods.

Authors:  Chun-Hsing Liao; Hsiang-Chi Kung; Gwo-Jong Hsu; Po-Liang Lu; Yung-Ching Liu; Chih-Ming Chen; Chun-Ming Lee; Wu Sun; Tsrang-Neng Jang; Ping-Cherng Chiang; Yu-Jen Cheng; Hsiu-Chen Lin; Zhi-Yuan Shi; Lih-Shinn Wang; Yin-Ching Chuang; Shih-Ming Tsao; Chin-Te Lu; Jien-Wei Liu; Cheng-Hua Huang; Po-Ren Hsueh
Journal:  Int J Antimicrob Agents       Date:  2008-11       Impact factor: 5.283

9.  Nationwide surveillance in Taiwan of the in-vitro activity of tigecycline against clinical isolates of Gram-positive cocci.

Authors:  Shih-Ming Tsao; Hsiu-Chen Lin; Chun-Ming Lee; Gwo-Jong Hsu; Chih-Ming Chen; Wu Sun; Yung-Ching Liu; Tsrang-Neng Jang; Yu-Jen Cheng; Po-Liang Lu; Ping-Chreng Chiang; Lih-Shinn Wang; Hsiang-Chi Kung; Yin-Ching Chuang; Zhi-Yuan Shi; Jien-Wei Liu; Cheng-Hua Huang; Chin-Te Lu; Chun-Hsing Liao; Po-Ren Hsueh
Journal:  Int J Antimicrob Agents       Date:  2008-11       Impact factor: 5.283

10.  Effect of different Mueller-Hinton agars on tigecycline disc diffusion susceptibility for Acinetobacter spp.

Authors:  Visanu Thamlikitkul; Surapee Tiengrim
Journal:  J Antimicrob Chemother       Date:  2008-06-21       Impact factor: 5.790

View more
  8 in total

1.  Randomized Noninferiority Trial of Cefoperazone-Sulbactam versus Cefepime in the Treatment of Hospital-Acquired and Healthcare-Associated Pneumonia.

Authors:  Jien-Wei Liu; Yen-Hsu Chen; Wen-Sen Lee; Jung-Chung Lin; Ching-Tai Huang; Hsi-Hsun Lin; Yung-Ching Liu; Yin-Ching Chuang; Hung-Jen Tang; Yao-Shen Chen; Wen-Chien Ko; Min-Chi Lu; Fu-Der Wang
Journal:  Antimicrob Agents Chemother       Date:  2019-07-25       Impact factor: 5.191

2.  Antimicrobial photodynamic therapy against clinical isolates of carbapenem-susceptible and carbapenem-resistant Acinetobacter baumannii.

Authors:  Mirian Marcolan De Mello; Patrícia Pimentel De Barros; Renata de Cassia Bernardes; Silvio Rubens Alves; Naiara Pires Ramanzini; Lívia Mara Alves Figueiredo-Godoi; Ana Carolina Chipoletti Prado; Antonio Olavo Cardoso Jorge; Juliana Campos Junqueira
Journal:  Lasers Med Sci       Date:  2019-03-20       Impact factor: 3.161

3.  Detection of antibiotic resistance profiles and aminoglycoside-modifying enzyme (AME) genes in high-level aminoglycoside-resistant (HLAR) enterococci isolated from raw milk and traditional cheeses in Turkey.

Authors:  Rahime Özdemir; Yasin Tuncer
Journal:  Mol Biol Rep       Date:  2020-01-27       Impact factor: 2.316

4.  Comparison of Minocycline Susceptibility Testing Methods for Carbapenem-Resistant Acinetobacter baumannii.

Authors:  Peng Wang; Sarah L Bowler; Serena F Kantz; Roberta T Mettus; Yan Guo; Christi L McElheny; Yohei Doi
Journal:  J Clin Microbiol       Date:  2016-09-14       Impact factor: 5.948

5.  Impacts of pretransplant infections on clinical outcomes of patients with acute-on-chronic liver failure who received living-donor liver transplantation.

Authors:  Kuo-Hua Lin; Jien-Wei Liu; Chao-Long Chen; Shih-Hor Wang; Chih-Che Lin; Yueh-Wei Liu; Chee-Chien Yong; Ting-Lung Lin; Wei-Feng Li; Tsung-Hui Hu; Chih-Chi Wang
Journal:  PLoS One       Date:  2013-09-02       Impact factor: 3.240

6.  Increased financial burdens and lengths of stay in patients with healthcare-associated infections due to multidrug-resistant bacteria in intensive care units: A propensity-matched case-control study.

Authors:  Li-Hsiang Su; I-Ling Chen; Ya-Fen Tang; Jen-Sin Lee; Jien-Wei Liu
Journal:  PLoS One       Date:  2020-05-18       Impact factor: 3.240

7.  Antibiotic consumption and healthcare-associated infections caused by multidrug-resistant gram-negative bacilli at a large medical center in Taiwan from 2002 to 2009: implicating the importance of antibiotic stewardship.

Authors:  I-Ling Chen; Chen-Hsiang Lee; Li-Hsiang Su; Ya-Feng Tang; Shun-Jen Chang; Jien-Wei Liu
Journal:  PLoS One       Date:  2013-05-30       Impact factor: 3.240

8.  Evaluating the performance characteristics of different antimicrobial susceptibility testing methodologies for testing susceptibility of gram-negative bacteria to tigecycline.

Authors:  Sima Babaei; Mehri Haeili
Journal:  BMC Infect Dis       Date:  2021-07-27       Impact factor: 3.090

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.